Bourgeon Capital Management LLC trimmed its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 1.1% during the first quarter, HoldingsChannel reports. The firm owned 21,327 shares of the medical instruments supplier’s stock after selling 247 shares during the period. Becton Dickinson and comprises 3.1% of Bourgeon Capital Management LLC’s holdings, making the stock its 13th biggest holding. Bourgeon Capital Management LLC’s holdings in Becton Dickinson and were worth $5,326,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BDX. Standard Life Aberdeen plc increased its holdings in shares of Becton Dickinson and by 2.5% during the third quarter. Standard Life Aberdeen plc now owns 129,845 shares of the medical instruments supplier’s stock valued at $33,890,000 after acquiring an additional 3,134 shares in the last quarter. Teachers Advisors LLC increased its holdings in Becton Dickinson and by 0.7% in the 3rd quarter. Teachers Advisors LLC now owns 488,441 shares of the medical instruments supplier’s stock worth $127,483,000 after buying an additional 3,366 shares during the period. Nordea Investment Management AB increased its holdings in Becton Dickinson and by 13.3% in the 3rd quarter. Nordea Investment Management AB now owns 13,206 shares of the medical instruments supplier’s stock worth $3,447,000 after buying an additional 1,548 shares during the period. B. Riley Wealth Management Inc. acquired a new position in Becton Dickinson and in the 3rd quarter worth approximately $201,000. Finally, Legal & General Group Plc increased its holdings in Becton Dickinson and by 0.6% in the 3rd quarter. Legal & General Group Plc now owns 1,187,399 shares of the medical instruments supplier’s stock worth $309,911,000 after buying an additional 7,170 shares during the period. 84.89% of the stock is currently owned by institutional investors.
In related news, CEO Vincent A. Forlenza sold 11,340 shares of the stock in a transaction on Monday, February 25th. The stock was sold at an average price of $250.40, for a total value of $2,839,536.00. Following the completion of the transaction, the chief executive officer now directly owns 227,250 shares of the company’s stock, valued at approximately $56,903,400. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Vincent A. Forlenza sold 3,123 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $255.03, for a total value of $796,458.69. Following the completion of the transaction, the chief executive officer now directly owns 215,372 shares of the company’s stock, valued at $54,926,321.16. The disclosure for this sale can be found here. Insiders have sold a total of 29,684 shares of company stock worth $7,518,574 in the last quarter. Insiders own 0.12% of the company’s stock.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $2.70 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.58 by $0.12. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The business had revenue of $4.16 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same quarter in the prior year, the firm posted $2.48 EPS. The business’s quarterly revenue was up 35.1% compared to the same quarter last year. Sell-side analysts expect that Becton Dickinson and Co will post 12.07 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Friday, June 7th will be given a $0.77 dividend. The ex-dividend date of this dividend is Thursday, June 6th. This represents a $3.08 annualized dividend and a yield of 1.29%. Becton Dickinson and’s dividend payout ratio is presently 27.97%.
BDX has been the topic of several research reports. Zacks Investment Research upgraded shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a report on Wednesday, April 10th. Raymond James cut their price target on shares of Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating on the stock in a report on Tuesday, March 19th. Piper Jaffray Companies increased their price target on shares of Becton Dickinson and to $274.00 and gave the stock an “overweight” rating in a report on Tuesday, February 5th. ValuEngine lowered Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Monday, April 1st. Finally, TheStreet upgraded Becton Dickinson and from a “c+” rating to an “a” rating in a research report on Tuesday, February 5th. Six analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $256.25.
COPYRIGHT VIOLATION WARNING: “Bourgeon Capital Management LLC Sells 247 Shares of Becton Dickinson and Co (BDX)” was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.baseballdailydigest.com/news/2019/05/04/bourgeon-capital-management-llc-sells-247-shares-of-becton-dickinson-and-co-bdx.html.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
See Also: Growth Stocks
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.